Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name TP53 positive
Gene Variant Detail

TP53 positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 positive Advanced Solid Tumor predicted - sensitive p28 Phase I Actionable In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360). 23449360
TP53 positive ovarian cancer predicted - sensitive NU6027 + Temozolomide Preclinical - Cell culture Actionable In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979). 21730979
TP53 positive Advanced Solid Tumor sensitive Serdemetan Phase I Actionable In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953). 21831953
TP53 positive breast cancer sensitive Serdemetan Phase I Actionable In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953). 21831953
TP53 positive Advanced Solid Tumor sensitive MVAp53 Phase I Actionable In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)). detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03363867 Phase II Atezolizumab + Bevacizumab + Cobimetinib BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON) Recruiting 1
NCT01042535 Phase Ib/II Ad.p53-DC vaccine + Indoximod Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer Completed USA 0
NCT03560882 Phase I Atorvastatin A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Recruiting USA 0
NCT02098343 Phase Ib/II Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 Completed USA | FRA | ESP | DEU | BEL 3
NCT03063203 Phase II Decitabine Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Terminated USA 0